Insmed Incorporated (NASDAQ:INSM), a global biopharmaceutical company focused on the needs of patients with rare diseases today announced the launch of NTM Facts, an educational campaign designed to raise awareness of nontuberculous mycobacterial (NTM) lung disease, a rare and often chronic infection that can lead to progressive inflammation and lung damage. There are currently no products indicated for the treatment of NTM lung disease in North America or Europe. The company’s campaign includes an interactive website, NTMfacts.com, designed to inform healthcare professionals about the signs, symptoms, and importance of proper diagnosis of NTM lung disease, as well as guideline-based options that may help physicians manage the condition. The launch of the company’s disease awareness campaign coincides with NTM Week, an American Thoracic Society (ATS) initiative to recognize rare lung disorders and foster interaction between patients and clinicians.
NTM lung infections are often difficult to diagnose or misdiagnosed because symptoms, such as chronic coughing, shortness of breath, and fatigue, may be similar to other lung conditions. On NTMfacts.com, healthcare providers can gain first-hand knowledge from the personal stories of patients who are living with the daily challenges of chronic NTM lung disease. NTMfacts.com also provides healthcare providers with a downloadable pocket guide for diagnosing, treating, and preventing NTM lung disease, which is based on the official statement of ATS and the Infectious Diseases Society of America (IDSA) published in 2007.
“Insmed is dedicated to raising awareness of NTM and we appreciate the importance of connecting physicians with the experiences of patients who are living with the devastating effects of this disease,” said Will Lewis, president and chief executive officer of Insmed. “We look forward to fostering increased awareness and education as part of our ongoing commitment to patients and physicians who are faced with numerous clinical challenges associated with diagnosing and managing NTM lung disease.”
“It is inspiring to see Insmed’s commitment to raising physicians’ awareness about the extensive physical and emotional impact of NTM lung disease,” said Philip Leitman, co-founder and president of NTM Info and Research, Inc., a non-profit organization formed on behalf of patients with pulmonary NTM disease. “Raising NTM awareness will help more patients receive a timely, proper diagnosis and assist physicians in assessing if treatment should be initiated to manage symptoms and disease progression.” (Original Source)
Shares of Insmed closed today at $16.97, up $0.15 or 0.89%. INSM has a 1-year high of $28.66 and a 1-year low of $12.65. The stock’s 50-day moving average is $22.24 and its 200-day moving average is $23.42.
On the ratings front, Insmed has been the subject of a number of recent research reports. In a report issued on October 6, H.C. Wainwright analyst Andrew Fein reiterated a Buy rating on INSM, with a price target of $35, which implies an upside of 106.6% from current levels. Separately, on September 23, Piper Jaffray’s Joshua Schimmer reiterated a Buy rating on the stock and has a price target of $51.
According to TipRanks.com, which ranks over 7,500 financial analysts and bloggers to gauge the performance of their past recommendations, Andrew Fein and Joshua Schimmer have a total average return of 4.8% and -10.3% respectively. Fein has a success rate of 41.3% and is ranked #1032 out of 3773 analysts, while Schimmer has a success rate of 24.6% and is ranked #3740.
Insmed Inc is a biopharmaceutical company engaged in developing and commercializing inhaled therapies for patients battling serious lung diseases that are often life threatening. Its products candidates includes ARIKAYCE.